| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HC-067047 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | JW-55 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.4 |
| mRNA | YK 4-279 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.4 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.036 | 0.4 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.06 | 0.4 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.5 |